2025-01-09 - Analysis Report
## Albemarle Corp (ALB) Stock Analysis Report

This report analyzes Albemarle Corp (ALB), a leading global producer of lithium and bromine-based specialty chemicals, based on the provided data.


**1. Performance Comparison with S&P 500 (VOO):**

Albemarle's cumulative return is -2.81%, while the S&P 500's is 115.41%.  The difference is a significant underperformance of -118.2%, placing it at the 1%ile based on the provided historical range of -121.6% to 228.8%.  The provided CAGR data shows significant volatility in performance over the years, with periods of substantial gains and losses.  This highlights the inherent risk associated with ALB, a company heavily reliant on commodity prices.


**2. Recent Price Movement:**

* **Closing Price:** $87.38
* **5-day Moving Average:** $88.11
* **20-day Moving Average:** $92.20
* **60-day Moving Average:** $98.35

The current price is below all three moving averages, suggesting a downward trend in the short to medium term.


**3. Technical Indicators & Expected Return:**

* **RSI (27.67):** Indicates the stock is in oversold territory, suggesting potential for a price rebound.
* **PPO (-0.04):** Shows a bearish momentum.
* **20-Day Relative Divergence (0.4):** Shows a short-term upward trend, potentially contradicting the PPO and moving average trends.
* **Expected Return (7490.6%):** This extremely high figure needs further context.  It likely represents an extraordinarily optimistic long-term (2+ years) projection and should be viewed with extreme skepticism unless the methodology for calculation is provided. The reliability of this prediction is highly questionable.  The current price of $87.38 is not highlighted as a point of significant change (no sharp increase or decrease is indicated).

**4. Recent Earnings Analysis:**

The latest quarterly earnings (2024-11-06) show a significant drop in EPS to -9.45 from 2.58 in the previous quarter (2024-05-01).  Revenue also declined from $2.31B to $1.35B.  This marks a substantial drop in both EPS and revenue compared to the previous quarters.  There is a notable inconsistency in the provided data (2024-11-06 appears twice, with different reported revenue), impacting the reliability of the analysis.  No information on earnings expectations is provided to assess "beats" or "misses."  Overall, the trend shows a severe decline in profitability.

**5. Financial Information Analysis:**

The financial data shows a concerning trend in profitability.  Profit margins have fluctuated wildly, going from positive to deeply negative over successive quarters.  While revenue was relatively consistent in 2024 Q1-Q3, it significantly dropped in Q4. Equity has also experienced fluctuations, reflecting the volatile nature of the business.  ROE has shifted from positive to negative over the past year, indicating deteriorating profitability.


**6. News and Recent Issues:**

This section requires information on recent earnings news (within the last two days), market outlook, and analyst opinions to provide a complete analysis.  This information is missing from the provided data.


**7. Overall Analysis:**

Albemarle is currently experiencing significant headwinds.  While the RSI suggests potential for a short-term rebound, the negative PPO, declining moving averages, drastically lowered EPS and profit margins, and volatile financial indicators paint a bearish picture.  The exceptionally high projected expected return is not credible without a clear explanation of its methodology.  The missing news and analyst data further limit the depth of this analysis.  Further investigation into the inconsistencies in the earnings data is crucial before drawing firm conclusions.  The significant price decline necessitates a thorough review of the underlying drivers of the company's performance, including commodity prices, market competition, and future growth prospects.  Caution is advised before considering any investment in ALB.


**8. Disclaimer:** This analysis is based solely on the data provided and should not be considered financial advice.  Independent research and consultation with a financial advisor are strongly recommended before making any investment decisions.
